Subcellular Clearance and Accumulation of Huntington Disease Protein: A Mini-Review by Ting Zhao et al.
MINI REVIEW
published: 21 April 2016
doi: 10.3389/fnmol.2016.00027
Subcellular Clearance and
Accumulation of Huntington Disease
Protein: A Mini-Review
Ting Zhao 1, Yan Hong 1, Xiao-Jiang Li 1,2* and Shi-Hua Li 1*
1 Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA, 2 State Key Laboratory of
Molecular Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing,
China
Edited by:
Ashok Hegde,
Georgia College and State University,
USA
Reviewed by:
Jose J. Lucas,
Centro de Biología Molecular Severo
Ochoa (CBMSO)-Universidad
Autónoma de Madrid (UAM), Spain
Nihar Ranjan Jana,
National Brain Research Centre, India
*Correspondence:
Xiao-Jiang Li
xli2@emory.edu;
Shi-Hua Li
sli@emory.edu
Received: 24 February 2016
Accepted: 01 April 2016
Published: 21 April 2016
Citation:
Zhao T, Hong Y, Li X-J and Li S-H
(2016) Subcellular Clearance and
Accumulation of Huntington Disease
Protein: A Mini-Review.
Front. Mol. Neurosci. 9:27.
doi: 10.3389/fnmol.2016.00027
Huntington’s disease (HD) is an autosomal dominant, progressive neurodegenerative
disease caused by an expanded polyglutamine (polyQ) tract in the N-terminal region
of mutant huntingtin (mHtt). As a result, mHtt forms aggregates that are abundant in
the nuclei and processes of neuronal cells. Although the roles of mHtt aggregates are
still debated, the formation of aggregates points to deficient clearance of mHtt in brain
cells. Since the accumulation of mHtt is a prerequisite for its neurotoxicity, exploring the
mechanisms for mHtt accumulation and clearance would advance our understanding of
HD pathogenesis and help us develop treatments for HD. We know that the ubiquitin-
proteasome system (UPS) and autophagy play important roles in clearing mHtt; however,
how mHtt preferentially accumulates in neuronal nuclei and processes remains unclear.
Studying the clearance of mHtt in neuronal cells is a challenge because neurons are
morphologically and functionally polarized, which means the turnover of mHtt may
be distinct in different cellular compartments. In this review, we discuss our current
knowledge about the clearance and accumulation of mHtt and strategies examining
mHtt clearance and accumulation in different subcellular regions.
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HUNTINGTON’S DISEASE AND SELECTIVE NEUROPATHOLOGY
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease that is
characterized by motor abnormalities, cognitive decline and psychiatric problems (Munoz-
Sanjuan and Bates, 2011). The disease is caused by the expansion of a trinucleotide CAG repeat in
exon 1 of the HD gene, which encodes an expanded polyglutamine (polyQ) tract in the N-terminal
region of mutant huntingtin (mHtt). While most HD patients carry CAG repeats in the range of
38–55 and develop neurological symptoms in mid-life, larger repeats (>60Q) can cause juvenile
onset HD (Ross et al., 2014).
Despite the ubiquitous expression of mHtt in the brain and peripheral tissues, the major
pathological feature of HD is selective neurodegeneration (Vonsattel and DiFiglia, 1998;
Munoz-Sanjuan and Bates, 2011). Similarly, selective neurodegeneration is also seen in many
other neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases, suggesting
that multiple factors may contribute to the selective neurodegeneration in these diseases.
Abbreviations: AAV, Adenoviral-associated vectors; HD, Huntington’s disease; HDAC6, Histone deacetylase 6;
LGP, Lateral globus pallidus; mHtt, Mutant huntingtin; polyQ, Polyglutamine; SN, Substantia nigra;
UPS, Ubiquitin-proteasome system.
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Given the known genetic mutation in HD and its well-
characterized neuropathology, HD makes an ideal model for
investigating how selective neuropathology occurs with aging. In
HD, neuronal degeneration is characterized by the preferential
loss of neuronal cells in the striatum in the early disease stage
and extensive neurodegeneration in a variety of brain regions
in later disease stages (Ross et al., 2014). This progressive
neurodegeneration is consistent with the late-onset neurological
symptoms of HD.
PREFERENTIAL ACCUMULATION OF mHtt
IN NEURONAL NUCLEI AND PROCESSES
The age-dependent neurodegeneration and neurological
symptoms in HD correlate with the accumulation of misfolded
forms of mHtt in neuronal cells. The expansion of the polyQ
repeat in mHtt causes the misfolding of mHtt and formation
of mHtt aggregates in neuronal nuclei and neuropils in HD
patient brains (DiFiglia et al., 1997; Gutekunst et al., 1999).
These aggregates are recognized by antibodies to the N-
terminal region of mHtt, suggesting that the aggregates are
formed by mHtt N-terminal fragments that are produced by
the proteolysis of full-length mHtt. Indeed, transgenic mice
expressing N-terminal mHtt show abundant mHtt aggregates
in their neuronal nuclei and processes (Davies et al., 1997;
Schilling et al., 1999). Studies of these transgenic HD mice also
demonstrate that N-terminal mHtt fragments preferentially
accumulate in neuronal cells to form nuclear aggregates and
neuropil aggregates. HD knock-in mice express full-length
mHtt at the endogenous level under the control of the mouse
Htt gene, and therefore mimic HD patients genetically. In HD
knock-in mice, mHtt also forms aggregates first in the neuronal
nuclei of the striatum (Wheeler et al., 2000; Li et al., 2001; Lin
et al., 2001). Although this preferential formation of neuronal
nuclei aggregates mirrors the vulnerability of striatal neurons in
HD patients, mHtt appears to form more neuropil aggregates
than nuclear aggregates in HD patients in early disease stages
(DiFiglia et al., 1997; Gutekunst et al., 1999). Despite this
species-dependent difference, in mice expressing full-length
mHtt and modeling early stages of HD, neuropil aggregates form
preferentially in the lateral globus pallidus (LGP) and substantia
nigra (SN; Li et al., 2001). The majority of striatal neurons extend
their axons to the LGP and SN, two brain regions degenerated
more significantly during the early stage of HD (Reiner et al.,
1988; Richfield et al., 1995). Thus, the preferential accumulation
of mHtt in both the neuropils and nuclei of striatal neurons
may account for the selective striatal neurodegeneration in
HD.
Many studies report that mHtt aggregates can be either
toxic or protective. It is possible that mHtt aggregates are
both harmful and beneficial depending on the disease stage,
subcellular localization and their association with other partners
or organelles. Nevertheless, because mHtt aggregates are
formed by N-terminal mHtt fragments that are misfolded, the
mHtt aggregates reflect the accumulation of misfolded mHtt.
Growing evidence indicates that the misfolded mHtt exerts its
neurotoxicity by disturbing a wide range of cellular functions
(Ross et al., 2014). The wide range of cellular toxicity from mHtt
is due perhaps to its ability to interact with a variety of proteins
and to interrupt the function of these interactors (Li and Li,
2004; Shirasaki et al., 2012) via a gain-of-function mechanism.
Thus, the accumulation of misfolded mHtt is a prerequisite to
its neuronal toxicity, and the clearance of mHtt is key to the
treatment of HD.
INTRACELLULAR CLEARANCE OF mHtt
Two proteolytic machineries are critical for clearing misfolded
proteins. One is the ubiquitin-proteasome system (UPS), which
mainly clears soluble and short-lived proteins in eukaryotic cells.
The other is autophagy, which removes long-lived proteins,
aggregated proteins and damaged organelles.
Because the formation of mHtt aggregates is age-dependent,
the initial notion was that mHtt impairs proteasomal function
(Bence et al., 2001; Venkatraman et al., 2004). However,
targeting expanded polyQ for proteasomal degradation did
not compromise proteasome activity (Michalik and Van
Broeckhoven, 2004). Also, mHtt-exon1, the shortest N-terminal
fragment of mHtt, was completely digested by the proteasome
(Juenemann et al., 2013). In addition, in vivo studies show
that proteasome activity in HD mouse brains is not perturbed
by mHtt expression (Wang et al., 2008a; Bett et al., 2009).
Although no global impairment of proteasomal activity is seen,
proteasomal dysfunction probably occurs in certain subcellular
regions, such as axonal terminals, which may lead to the
accumulation of mHtt in these places (Wang et al., 2008a). It
is established that mHtt compromises the axonal transport of
mitochondria (Orr et al., 2008; Reddy and Shirendeb, 2012).
Since the UPS is a highly ATP-dependent system (Schrader
et al., 2009), defective mitochondria transport may lead to ATP
deficiency in neurites and nerve terminals, which can impair
the local degradation of mHtt by the proteasome and causes the
aggregation of mHtt in these subcellular regions.
Using various HD cell and animal models, previous studies
have shown that upregulation of autophagy leads to a reduction
of mHtt aggregates, indicating that autophagy plays a role in the
clearance of mHtt aggregates (Qin et al., 2003; Sasazawa et al.,
2015). K63-linked polyubiquitination on mHtt is proposed to
confer the selectivity on the degradation of mHtt aggregates by
autophagy since K63-ubiquitinated substrates are recognized by
autophagy receptors, such as p62, which has been shown to bind
Htt (Tan et al., 2008). However, Bhat et al. (2014) found that
ubiquitination of K48 linkage on mHtt switches to K63 linkage
with aging, which promotes aggregation. On the other hand,
mHtt compromises autophagy by perturbing cargo recognition
and autophagosome motility (Martinez-Vicente et al., 2010;
Wong and Holzbaur, 2014). Since the ubiquitination of both K48
and K63 is involved in the clearance of misfolded proteins by the
UPS and autophagy, how the UPS and autophagy work together
to remove mHtt remains to be clarified. Histone deacetylase
6 (HDAC6) probably links autophagy to UPS for clearance
of mHtt as autophagy is activated in an HDAC6-dependent
manner when proteasomal function is impaired (Pandey et al.,
2007).
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STRATEGIES TO EXAMINE SUBCELLULAR
mHtt CLEARANCE AND ACCUMULATION
Given the fact that mHtt preferentially accumulates in neuronal
nuclei and processes, it is important to determine mHtt clearance
at the subcellular level. Nuclei and synaptosomes can be
isolated via biochemical fractionation, and the fractions can
be analyzed by Western blotting. The advantage of this assay
is that aggregated and monomer proteins can be separated in
SDS gel and assessed for their relative levels on the same blot.
Quantifying the levels of soluble and aggregated mHtt can yield
valuable information about the levels of mHtt in these subcellular
regions; however, the combination of subcellular fractionation
and western blotting cannot monitor the degradation of mHtt
in real time. Moreover, it is difficult to separate the fraction
that is enriched in neuronal processes or neuropil. In addition,
fractionation requires the use of brain homogenates that
cannot distinguish cell types in which mHtt may differentially
accumulate or be cleared.
It is not feasible to study the degradation of mHtt in living
neurons until phototransformable fluorescent proteins are
invented. Phototransformable fluorescent proteins can be
classified into three types-photoactivating, photoconverting and
photoswitching-based on their responses to light. Currently,
these proteins are used widely to study the dynamics of
molecules and cells in a spatiotemporal manner (Adam
et al., 2014). Tsvetkov et al. (2013) recently used Dendra2,
one of the photoconvertible fluorescent proteins, to study
the degradation of mHtt-exon1 in cultured striatal neurons.
Dendra2 is a green-to-red photoconvertible fluorescent protein
featuring fast maturation and bright fluorescence (Chudakov
et al., 2007). Light irradiation at a 405-nm wavelength can
efficiently activate Dendra2 and consequently switches its
fluorescent color irreversibly from green to red. The linkage
of Dendra2 to mHtt does not perturb its neurotoxicity or
the property of aggregation in neurons. After transient
transfection of Htt-exon1-Dendra2 into striatal neurons,
Tsvetkov et al. (2013) converted green Htt-exon1-Dendra2
to red fluorescence by activating Dendra2 with 405-nm laser
light. Therefore, after irradiation, the reduction of red Htt-
exon1 over time reflects its degradation in live cells. Using
this strategy, called the ‘‘optical pulse chase’’ assay, Tsvetkov
et al. (2013) found that mHtt-exon1 was cleared faster than
its wild-type counterpart in the body of the cultured striatal
neurons.
Although optical pulse chase has been used mainly with in
vitro cultured cells, it should also be useful for determining
the turnover of mHtt in live cells at subcellular levels, such
as neuronal processes and terminals. Examining the change
of red fluorescence avoids the potential influence from newly
synthesized proteins as they are labeled by inactive green
Dendra2, so that the degradation of mHtt can be quantified.
The Dentra-2 fusion proteins can be expressed via adenoviral-
associated vectors (AAV), and stereotaxic injection would allow
the delivery of the AAV vectors to specific brain regions,
such as the striatum. The injected brain region can then be
isolated and sectioned into brain slices, which can be observed
in medium under a fluorescent microscope. Photoconversion
of Dendra-2 will then be achieved to measure the clearance
of mHtt in neuronal processes or nerve terminals in brain
slices. Moreover, using different promoters would confer the
expression of Dendra-2-mHtt in specific types of cells, making
it possible to study the cell type-dependent degradation of mHtt
in the brain. Further, tagging the Dendra-2 fusion protein with
organelle targeting sequences would allow us to study mHtt’s
degradation in specific organelles. Given that suppression of
neuropil aggregates ameliorated the neurological symptoms of
HD mice (Wang et al., 2008b), promoting clearance of mHtt
by the UPS in neuropils should be therapeutically beneficial
for HD. In support of this idea, overexpressing ube3a, an
ubiquitin E3 ligase, can activate the UPS and decrease mHtt
aggregates in the brains of HD knock-in mice (Bhat et al., 2014).
In addition, up-regulating autophagy has also been found to
eliminate mHtt aggregates. (Ravikumar et al., 2004; Sasazawa
et al., 2015).
CONCLUSION
Although mHtt is known to be cleared by the UPS and
autophagy, how mHtt is cleared at the subcellular level remains
unknown. Understanding this interesting issue will shed light on
the pathogenesis of HD and also help us find ways of accelerating
the clearance of this toxic protein. Biochemical fractionation
would allow one to simultaneously examine the relative levels
of aggregated and monomer mHtt on the same Western blot.
The optical pulse chase assay would enable the study of the
degradation of mHtt in different subcellular regions in living
neurons. Such studies will answer the question of whether mHtt
degradation is subcellular region dependent and could also be
extended to studies of other types of misfolded proteins in
different neurodegenerative diseases.
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